Skip to main content

Advertisement

SpringerLink
Log in

A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Characteristics of taxane-induced peripheral neuropathy (PN) could be different between paclitaxel and nab-paclitaxel. The purpose of this prospective observational multicenter cohort study was to compare tri-weekly nab-paclitaxel to weekly standard paclitaxel regarding the severity, onset and recovery of sensory and motor PN in patients with breast cancer.

Methods

Patients with histologically confirmed breast cancer who were scheduled to receive standard weekly paclitaxel (80 mg/m2) or tri-weekly nab-paclitaxel (260 mg/m2) at institutions in our multicenter group were eligible for this study. Sensory and motor PN were evaluated every 3 weeks until PN improved for up to one year using patient-reported outcome.

Results

Between February 2011 and April 2013, 115 patients were enrolled, including 57 and 58 in the paclitaxel and nab-paclitaxel groups, respectively. The incidence of moderate or severe sensory PN was not significantly different between the two groups (p = 0.40). The incidence of moderate or higher motor PN was more frequent in the nab-paclitaxel group than in the paclitaxel group (p = 0.048). The median period for demonstrating PN were shorter in the nab-paclitaxel group than in the paclitaxel group (sensory, p = 0.003; motor, p = 0.001). The recovery of motor PN was slower in the nab-paclitaxel group than in the paclitaxel group (p = 0.035), while the recovery period of sensory PN was not statistically different.

Conclusion

Nab-paclitaxel induced sensory PN sooner than paclitaxel, and no difference was observed in the severity and recovery duration between the two agents. Motor PN was more severe, started sooner, and improved over a longer period in the nab-paclitaxel-treated patients than in the paclitaxel-treated patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The data that support the findings of this study are available on request from the corresponding author upon reasonable request.

Abbreviations

PN:

Peripheral neuropathy

CIPN:

Chemotherapy-induced peripheral neuropathy

CTCAE:

Common Terminology Criteria for Adverse Events

PRO:

Patient-reported outcome

PNQ:

Patient Neurotoxicity Questionnaire

ER:

Estrogen receptor

CI:

Confidence interval

RR:

Risk ratio

References

  1. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–8.

    Article  CAS  PubMed  Google Scholar 

  2. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6:489–94.

    Article  CAS  PubMed  Google Scholar 

  3. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. Description of a short-term taxol-induced nociceptive neuropathy in rats. Brain Res. 2000;887:239–49.

    Article  CAS  PubMed  Google Scholar 

  4. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004;15:1358–65.

    Article  CAS  PubMed  Google Scholar 

  5. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24:1633–42.

    Article  CAS  PubMed  Google Scholar 

  6. Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther. 2007;7:919–43.

    Article  CAS  PubMed  Google Scholar 

  7. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–803.

    Article  CAS  PubMed  Google Scholar 

  8. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041–53.

    Article  CAS  PubMed  Google Scholar 

  9. Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75:659–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sahenk Z, Barohn R, New P, Mendell JR. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol. 1994;51:726–9.

    Article  CAS  PubMed  Google Scholar 

  11. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr. 1993;15:107–15.

    Google Scholar 

  12. Bissery MC. Preclinical pharmacology of docetaxel. Eur J Cancer. 1995;31A(Suppl 4):S1-6.

    Article  CAS  Google Scholar 

  13. Boer HH, Moorer-van Delft CM, Muller LJ, Kiburg B, Vermorken JB, Heimans JJ. Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis. J Neurooncol. 1995;25:49–57.

    Article  CAS  PubMed  Google Scholar 

  14. Windebank AJ. The vehicle for cyclosporine is neurotoxic in vitro. Ann Neurol. 1997;41:563–4.

    Article  CAS  PubMed  Google Scholar 

  15. Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther. 1994;268:1051–6.

    CAS  PubMed  Google Scholar 

  16. Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G, et al. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol. 2007;25:5070–7.

    Article  PubMed  Google Scholar 

  17. Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings? Qual Life Res. 1997;6:225–36.

    Article  CAS  PubMed  Google Scholar 

  18. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998;9:739–44.

    Article  CAS  PubMed  Google Scholar 

  19. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33:15–49.

    Article  CAS  PubMed  Google Scholar 

  20. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009;17:1483–91.

    Article  PubMed  Google Scholar 

  21. Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, et al. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer. 2009;17:1071–80.

    Article  PubMed  Google Scholar 

  22. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, et al. Randomized phase III Trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or Ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015;33:2361–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Tsurutani J, Hara F, Kitada M, Takahashi M, Kikawa Y, Kato H, et al. Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. Breast. 2021;55:63–8.

    Article  PubMed  Google Scholar 

  24. Tanaka S, Iwamoto M, Kimura K, Matsunami N, Morishima H, Yoshidome K, et al. Phase II study of neoadjuvant anthracycline-based regimens combined with nanoparticle albumin-bound paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive operable breast cancer. Clin Breast Cancer. 2015;15:191–6.

    Article  CAS  PubMed  Google Scholar 

  25. Frigeni B, Piatti M, Lanzani F, Alberti P, Villa P, Zanna C, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute common toxicity scale. J Peripher Nerv Syst. 2011;16:228–36.

    Article  PubMed  Google Scholar 

  26. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46:479–94.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Editage [http://www.editage.jp] for editing and reviewing this manuscript for English language.

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery and Surgical Oncology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan

    Kumiko Kida, Akimitsu Yamada, Sadatoshi Sugae & Itaru Endo

  2. Department of Breast Surgical Oncology, St. Luke’s International Hospital, Tokyo, Japan

    Kumiko Kida

  3. Department of Breast Surgery, Yokohama Municipal Citizen’s Hospital, Kanagawa, Japan

    Kazuhiro Shimada

  4. Department of Surgery, Yokohama Saiseikai Nanbu Hospital, Kanagawa, Japan

    Kazuhiro Shimada

  5. Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Kanagawa, Japan

    Kazutaka Narui

  6. Department of Breast Surgery, Fujisawa City Hospital, Kanagawa, Japan

    Sadatoshi Sugae

  7. Department of Breast Surgery, Yokohama Minato Red Cross Hospital, Kanagawa, Japan

    Daisuke Shimizu

  8. Department of Breast Surgery, Shonan Memorial Hospital, Kanagawa, Japan

    Takako Doi

  9. Department of Medical Statistics, Toho University, Tokyo, Japan

    Mari Oba

  10. Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan

    Takashi Ishikawa

Authors
  1. Kumiko Kida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akimitsu Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhiro Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazutaka Narui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sadatoshi Sugae
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daisuke Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takako Doi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mari Oba
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Itaru Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takashi Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akimitsu Yamada.

Ethics declarations

Conflict of interest

All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 564 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kida, K., Yamada, A., Shimada, K. et al. A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer. Breast Cancer 31, 409–416 (2024). https://doi.org/10.1007/s12282-024-01551-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-024-01551-z

Keywords

Search

Navigation